An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A
Latest Information Update: 25 Jul 2022
Price :
$35 *
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Factor VIII stimulants
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms Kids A-LONG; Kids ALONG
- Sponsors Biogen; Bioverativ
- 14 Mar 2021 Results of population pharmacokinetic model from NCT01027377, NCT01181128 and NCT01458106 published in the Journal of Clinical Pharmacology
- 10 May 2019 According to a Swedish Orphan Biovitrum media release, final pooled post-hoc analysis data from A-LONG, Kids A-LONG and ASPIRE studies will be presented at the World Federation of Hemophilia's 16th International Musculoskeletal Congress (MSK).
- 24 Apr 2019 According to a Swedish Orphan Biovitrum media release, long term safety and efficay data was presented at the European Association of Haemophilia and Allied Disorders (EAHAD) conference.